Table 4.
Model Parameter | Base Case Value (Range) | References |
---|---|---|
SVR Rates | ||
SOF/RBV | ||
F0-F4 | 0.70 (0.52–0.84) | (7–10) |
SOF/SMV | ||
Q80K+ | ||
F0-F2 | 0.89 (0.80–0.98) | (13) |
F3-F4 | 0.91 (0.82–0.98) | (13) |
Q80K- | ||
F0-F4 | 0.98 (0.88–0.98) | (13) |
SOF/LDV | ||
F0-F4 | 0.96 (0.90–0.98) | (27) |
Re-treatment | ||
Proportion re-treated after initial treatment failure | 0.90 (0.80–1.0) | Estimation |
Disease Progression after SVR (annual rates) | ||
F3 SVR to decompensated cirrhosis | 0.0010 (0.0008–0.0012) | (28, 36) |
F3 SVR to HCC | 0.007 (0.006–0.008) | (28, 36) |
F4 SVR to decompensated cirrhosis | 0.003 (0.002–0.004) | (28, 36) |
F4 SVR to HCC | 0.019 (0.015–0.023) | (28, 36) |
Fibrosis Regression after SVR (proportions) | ||
F3 to F2 | 0.50 (0.25–0.82) | (22–24, 26) |
F4 to F2 | 0.08 (0.06–0.10) | (25) |
F4 to F3 | 0.34 (0.19–0.49) | (22, 24, 26) |
Abbreviations: CHC = chronic hepatitis C; F0-F4 = Metavir fibrosis stages; HCC = hepatocellular carcinoma; LDV = ledipasvir; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response
Values in tables have been rounded. For full decimal places, consult cited sources.